NEW RAY MEDICINE INTERNATIONAL HOLDING LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.036 HKD | 0.00% |
|
-2.70% | -28.00% |
| Mar. 25 | New Ray Medicine International Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 18 | New Ray Medicine International Forecasts Decline in 2023 Loss | MT |
| Sales 2021 | 335M 42.83M | Sales 2022 | 89.77M 11.46M | Capitalization | 159M 20.28M |
|---|---|---|---|---|---|
| Net income 2021 | -2M -255K | Net income 2022 | -77M -9.83M | EV / Sales 2021 | 1.71 x |
| Net cash position 2021 | 137M 17.53M | Net cash position 2022 | 153M 19.55M | EV / Sales 2022 | 0.06 x |
| P/E ratio 2021 |
-250
x | P/E ratio 2022 |
-2.04
x | Employees | 23 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.66% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -2.70% | ||
| Current month | +2.86% | ||
| 1 month | -2.70% | ||
| 3 months | -12.20% | ||
| 6 months | -20.00% | ||
| Current year | -28.00% |
1 week
0.03
0.04
1 month
0.030.05
Current year
0.030.05
1 year
0.030.08
3 years
0.032.76
5 years
0.032.76
10 years
0.035.00
| Managers | Title | Age | Since |
|---|---|---|---|
Qiuqin Wang
CEO | Chief Executive Officer | 46 | 18-06-26 |
Zhi Hong Huo
BRD | Director/Board Member | 45 | 18-06-26 |
Yat Sing Ng
SEC | Corporate Secretary | - | 23-07-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lai Yin Sy
BRD | Director/Board Member | 44 | 18-09-23 |
Chi Kin Leung
BRD | Director/Board Member | 74 | 13-09-25 |
Sin Ming Li
BRD | Director/Board Member | 48 | 17-06-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.036 | 0.00% | 1,499,200 |
| 24-04-23 | 0.036 | +5.88% | 112,000 |
| 24-04-22 | 0.034 | 0.00% | 88,000 |
| 24-04-19 | 0.034 | -2.86% | 656,000 |
| 24-04-18 | 0.035 | -7.89% | 916,800 |
Delayed Quote Hong Kong S.E., April 24, 2024 at 04:08 am EDT
More quotes
New Ray Medicine International Holding Limited is an investment holding company principally engaged in the trading of pharmaceutical products in China. The Company operates its business through four segments. The Injection Drugs segment is engaged in the trading of injection drugs. The Capsule and Granule Drugs segment is engaged in the trading of capsule and granule drugs. The Tablet Drugs segment is engaged in the trading of tablet drugs. The Others segment is engaged in the trading of miscellaneous types of goods and drugs.
Sector
Drug Retailers
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.00% | 7.68M | |
| -31.79% | 15.57B | |
| -36.19% | 9.81B | |
| +9.74% | 6.08B | |
| -10.45% | 6.03B | |
| -35.14% | 5.52B | |
| -0.73% | 4.75B | |
| +52.93% | 4.23B | |
| -11.96% | 3.6B | |
| -5.68% | 3.16B |
- Stock Market
- Equities
- 6108 Stock
